BACKGROUND: Use of non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with a reduced risk of several cancers. This is thought to be through the inhibitory action on the cyclooxygenase (COX) enzyme, COX-2. Evidence for NSAIDs preventing head and neck cancer (HNC) is conflicting. We conducted a systematic literature review to investigate the association between NSAID/aspirin use and risk of head and neck cancer (HNC). METHODOLOGY: MEDLINE, EMBASE, PubMed, Cochrane Library, and Web of Science were systematically searched using terms for NSAIDs/aspirin, HNC, and observational/intervention study designs to identify studies published by December 2009. RESULTS: Of 9,268 articles identified, two population-based prescribing database studies and three case-control studies met the selection criteria. The studies investigated different HNC sites. Only one study found a significant protective association of aspirin use with HNC risk (OR 0.75, 95% CI 0.58-0.96), and one showed a significantly increased risk of oral/oropharyngeal cancer with non-low-dose aspirin NSAID use (OR 3.5, 95% CI 1.8-6.7). Many of the studies identified lacked information on important confounding factors. CONCLUSION: No definitive conclusion on the effect of NSAIDs/aspirin on HNC risk was possible. Aspirin may protect against HNC, although further robust large-scale studies are required to clarify any possible association.
BACKGROUND: Use of non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with a reduced risk of several cancers. This is thought to be through the inhibitory action on the cyclooxygenase (COX) enzyme, COX-2. Evidence for NSAIDs preventing head and neck cancer (HNC) is conflicting. We conducted a systematic literature review to investigate the association between NSAID/aspirin use and risk of head and neck cancer (HNC). METHODOLOGY: MEDLINE, EMBASE, PubMed, Cochrane Library, and Web of Science were systematically searched using terms for NSAIDs/aspirin, HNC, and observational/intervention study designs to identify studies published by December 2009. RESULTS: Of 9,268 articles identified, two population-based prescribing database studies and three case-control studies met the selection criteria. The studies investigated different HNC sites. Only one study found a significant protective association of aspirin use with HNC risk (OR 0.75, 95% CI 0.58-0.96), and one showed a significantly increased risk of oral/oropharyngeal cancer with non-low-dose aspirin NSAID use (OR 3.5, 95% CI 1.8-6.7). Many of the studies identified lacked information on important confounding factors. CONCLUSION: No definitive conclusion on the effect of NSAIDs/aspirin on HNC risk was possible. Aspirin may protect against HNC, although further robust large-scale studies are required to clarify any possible association.
Authors: Fatma M Shebl; Ann W Hsing; Yikyung Park; Albert R Hollenbeck; Lisa W Chu; Tamra E Meyer; Jill Koshiol Journal: PLoS One Date: 2014-12-31 Impact factor: 3.240
Authors: Austin J Iovoli; Gregory M Hermann; Sung Jun Ma; Alexis J Platek; Mark K Farrugia; Edwin Yau; Kimberly E Wooten; Hassan Arshad; Vishal Gupta; Moni A Kuriakose; Wesley L Hicks; Anurag K Singh Journal: JAMA Netw Open Date: 2020-06-01
Authors: Tudor I Oprea; Larry A Sklar; Jacob O Agola; Yuna Guo; Melina Silberberg; Joshua Roxby; Anna Vestling; Elsa Romero; Zurab Surviladze; Cristina Murray-Krezan; Anna Waller; Oleg Ursu; Laurie G Hudson; Angela Wandinger-Ness Journal: PLoS One Date: 2015-11-11 Impact factor: 3.240